All Pfizer articles – Page 3
-
-
Business
Heptares takes on new partners for drug discovery
Firm set to receive over $1bn from research partnerships
-
Business
Pfizer to close Cambridge pain outpost
120 jobs under threat from closure of Neusentis subsidiary R&D site
-
News
Pfizer’s response to compound fraud spotlights quality issues
‘Bosutinib isomer’ typifies threat posed by evolution of chemical supply chain
-
Business
Pfizer and Allergan agree mega-merger
$160 billion deal allows Pfizer to escape US tax system by re-homing in Ireland
-
Opinion
Human capital
Business leader: Incubators and hubs for small and medium-sized enterprises are all the fashion
-
Business
Merger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Cancer Drugs Fund axes 23 treatments
The UK government has cut down the list of cancer therapies it will pay for through the Cancer Drugs Fund
-
Business
Hospira buyout is a shot in the arm for Pfizer’s biosimilars
$17bn deal, intended to bolster sterile injectable and biologics capabilities, will be financed with existing cash and new debt
-
-
Business
Big pharma opens up abandoned drugs
Seven firms will make 68 stalled compounds available for academic research
-
Business
Clinical collaborations drive cancer immunotherapy
Companies race to pair up chemotherapy drugs with immune system-boosting antibodies to greatest effect in trials
-
Business
Inhaled insulin approved in US
European committee recommends approval for generic long-acting insulin
-
Business
Drug giants settle mismarketing lawsuits
Pfizer and GSK settle claims over promoting drugs for unapproved uses in the US
-
Business
Drug companies rapped for anticompetitive behaviour
Italian authorities demand €1.2 billion in damages from Roche, Novartis and Pfizer
-
Opinion
Messy megamergers
Big company buyouts are more about immediate gains and rarely consider the impact on research, says Derek Lowe
-
Business
Time called on Pfizer–AstraZeneca deal
Pfizer could make a fresh approach after six months under City takeover rules
-
Business
AstraZeneca refuses Pfizer’s ‘final’ offer
Pfizer pledges not to make hostile bid direct to shareholders
-
Business
Pfizer presses hard for AstraZeneca deal
Executives face down international controversy over tax schemes and previous post-merger record
- Previous Page
- Page1
- Page2
- Page3
- Page4
- Next Page